Abbott Directed to Provide Prescribing Details for Triamcinolone Hexacetonide Pre-Filled Syringe
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has instructed Abbott Healthcare Pvt. to submit proposed prescribing information and supporting data for Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml (Pre-filled syringe). This directive follows a detailed review of the company's proposal during the SEC meeting on September 17, 2025, at CDSCO headquarters in New Delhi.
During the meeting, Abbott presented its proposal for introducing Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml Pre-filled Syringe for use in already approved indications. The firm also submitted a detailed justification of the rationale and clinical need for this new pre-filled syringe presentation of the drug.
Author's summary: Abbott must provide prescribing details and data.
More News
- Three resilient UK multinationals global managers are excited about | Trustnet
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Philippines economy to grow 5.6% in 2025 – Fitch
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- The new age of pediatric medication awareness - Express Healthcare
- 2 US Navy aircraft crash in South China Sea
- West Indies ease past Bangladesh in first T20I
- ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times - Clinical Insights for Eye Specialists
- Partnerships to innovate access to medicines - BusinessWorld Online
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado